title: Direct oral anticoagulants and the bleeding patient.
authors.affiliation: Division of Emergency Medicine (Wood, Ackery) and Division of Hematology (Sholzberg), Department of Medicine, University of Toronto; Division of Hematopathology (Sholzberg), Coagulation Laboratory and Pathobiology, Department of Laboratory Medicine, University of Toronto; and St. Michael's Hospital (Ackery, Sholzberg), Toronto, Ont.
authors.forename: Brendan
authors.initials: B
authors.lastname: Wood
authors.affiliation: Division of Emergency Medicine (Wood, Ackery) and Division of Hematology (Sholzberg), Department of Medicine, University of Toronto; Division of Hematopathology (Sholzberg), Coagulation Laboratory and Pathobiology, Department of Laboratory Medicine, University of Toronto; and St. Michael's Hospital (Ackery, Sholzberg), Toronto, Ont.
authors.forename: Michelle
authors.initials: M
authors.lastname: Sholzberg
authors.affiliation: Division of Emergency Medicine (Wood, Ackery) and Division of Hematology (Sholzberg), Department of Medicine, University of Toronto; Division of Hematopathology (Sholzberg), Coagulation Laboratory and Pathobiology, Department of Laboratory Medicine, University of Toronto; and St. Michael's Hospital (Ackery, Sholzberg), Toronto, Ont. alun.ackery@mail.utoronto.ca.
authors.forename: Alun
authors.initials: A
authors.lastname: Ackery
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000925:Anticoagulants / Q000009:adverse effects*; D000931:Antidotes / Q000627:therapeutic use; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D000991:Antithrombins / Q000009:adverse effects; D001779:Blood Coagulation Factors / Q000627:therapeutic use*; D002606:Charcoal / Q000627:therapeutic use; D000069604:Dabigatran / Q000009:adverse effects; D065427:Factor Xa Inhibitors / Q000009:adverse effects; D006207:Half-Life; D006470:Hemorrhage / Q000139:chemically induced / Q000628:therapy*; D006801:Humans; D011720:Pyrazoles / Q000009:adverse effects; D011728:Pyridones / Q000009:adverse effects; D006435:Renal Dialysis; D000069552:Rivaroxaban / Q000009:adverse effects; D014148:Tranexamic Acid / Q000627:therapeutic use*; D014859:Warfarin / Q000009:adverse effects
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; D000931:Antidotes; D000933:Antifibrinolytic Agents; D000991:Antithrombins; D001779:Blood Coagulation Factors; D065427:Factor Xa Inhibitors; D011720:Pyrazoles; D011728:Pyridones; D002606:Charcoal; C025667:prothrombin complex concentrates; C522181:apixaban; D014859:Warfarin; D014148:Tranexamic Acid; C000594745:idarucizumab; D000069552:Rivaroxaban; D000069604:Dabigatran